S Janssen1, D Rades1, A Meyer2, F B Fahlbusch3, I Wildfang4, A Meier5, S Schild6, H Christiansen5, C Henkenberens7. 1. Department of Radiation Oncology, University of Luebeck, Luebeck, Germany. 2. Medical Practice for Radiotherapy and Radiation Oncology, Hildesheim, Germany. 3. Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-University of Erlangen-Nuernberg, Nuremberg, Germany. 4. Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany. 5. Department of Radiotherapy and Special Oncology, Hannover Medical School, Hannover, Germany. 6. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, USA. 7. Department of Radiotherapy and Special Oncology, Hannover Medical School, Hannover, Germany. henkenberens.christoph@mh-hannover.de.
Abstract
PURPOSE: To assess the outcome of breast cancer patients with local recurrence who underwent partial external beam re-irradiation (re-RT) either as part of a second breast-conserving therapy or following mastectomy. METHODS: Between 03/2004 and 10/2016, 83 breast cancer patients with local recurrence were treated with surgery followed by re-RT. The re-RT schedules were 45 Gy (1.8 Gy per fraction) administered either to the partial breast (n = 42) or mastectomy scar (n = 41). The patients and tumor characteristics predictive of local control, distant control, and survival (overall and breast-cancer specific) were evaluated by univariate and multivariate analyses. RESULTS: The median follow-up was 35 months (range 3-143 months). The median time interval between the first irradiation and re-RT was 117 months (range 16-357 months). The prognostic factors for favorable overall survival rates were younger age (p = 0.045), lower T‑category (p = 0.019), and N0 category (p = 0.005). N0 was also superior to N+ with respect to outfield recurrences (p = <0.001) and breast cancer-specific survival (p = 0.025). Acute and late skin toxicity was generally low (<grade 3). CONCLUSION: Re-RT with 45 Gy (1.8 Gy per fraction) for partial breast or mastectomy scar after the second surgery resulted in high local control rates and tolerable skin toxicity.
PURPOSE: To assess the outcome of breast cancerpatients with local recurrence who underwent partial external beam re-irradiation (re-RT) either as part of a second breast-conserving therapy or following mastectomy. METHODS: Between 03/2004 and 10/2016, 83 breast cancerpatients with local recurrence were treated with surgery followed by re-RT. The re-RT schedules were 45 Gy (1.8 Gy per fraction) administered either to the partial breast (n = 42) or mastectomy scar (n = 41). The patients and tumor characteristics predictive of local control, distant control, and survival (overall and breast-cancer specific) were evaluated by univariate and multivariate analyses. RESULTS: The median follow-up was 35 months (range 3-143 months). The median time interval between the first irradiation and re-RT was 117 months (range 16-357 months). The prognostic factors for favorable overall survival rates were younger age (p = 0.045), lower T‑category (p = 0.019), and N0 category (p = 0.005). N0 was also superior to N+ with respect to outfield recurrences (p = <0.001) and breast cancer-specific survival (p = 0.025). Acute and late skin toxicity was generally low (<grade 3). CONCLUSION: Re-RT with 45 Gy (1.8 Gy per fraction) for partial breast or mastectomy scar after the second surgery resulted in high local control rates and tolerable skin toxicity.
Entities:
Keywords:
Breast cancer recurrence; Breast conserving surgery; External beam radiotherapy; Mastectomy; Partial re-irradiation
Authors: Sabine Oldenborg; Rob M Van Os; Caroline M Van rij; Johannes Crezee; Jeroen B Van de Kamer; Emiel J T Rutgers; Elisabeth D Geijsen; Paul J Zum vörde sive vörding; Caro C E Koning; Geertjan Van tienhoven Journal: Int J Hyperthermia Date: 2010 Impact factor: 3.914
Authors: Akke Bakker; M Willemijn Kolff; Rebecca Holman; Caspar M van Leeuwen; Linda Korshuize-van Straten; Rianne de Kroon-Oldenhof; Coen R N Rasch; Geertjan van Tienhoven; Hans Crezee Journal: Int J Radiat Oncol Biol Phys Date: 2017-02-16 Impact factor: 7.038
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: Ishita Chen; Astrid M Botty Van den Bruele; Erin F Gillespie; Boris A Mueller; Amy J Xu; John Cuaron; Atif J Khan; Beryl McCormick; Oren Cahlon; Simon N Powell; Hiram Cody; Lior Z Braunstein Journal: Breast Cancer Res Treat Date: 2021-03-26 Impact factor: 4.872
Authors: Prashant Gabani; Hetal Patel; Maria A Thomas; Beth Bottani; S Murty Goddu; William Straube; Julie A Margenthaler; Laura Ochoa; Jeff D Bradley; Imran Zoberi Journal: Clin Transl Radiat Oncol Date: 2019-10-02
Authors: Constanze Elfgen; U Güth; G Gruber; S Birrer; V Bjelic-Radisic; M Fleisch; C J Tausch Journal: Breast Cancer Date: 2020-06-01 Impact factor: 4.239